Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Alpha-galactosylceramide … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines

Artikel i vetenskaplig tidskrift
Författare C. J. H. Davitt
S. Longet
A. Albutti
V. Aversa
Stefan Nordqvist
B. Hackett
C. P. McEntee
M. Rosa
I. S. Coulter
Michael Lebens
Joshua Tobias
Jan Holmgren
E. C. Lavelle
Publicerad i Mucosal Immunology
Volym 12
Sidor 1055–1064
ISSN 1933-0219
Publiceringsår 2019
Publicerad vid Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi
Sidor 1055–1064
Språk en
Länkar dx.doi.org/10.1038/s41385-019-0159-...
Ämneskategorier Immunologi inom det medicinska området

Sammanfattning

Cholera is a severe diarrheal disease caused by the bacterium Vibrio cholerae (V. cholerae) that results in 3–4 million cases globally with 100,000–150,000 deaths reported annually. Mostly confined to developing nations, current strategies to control the spread of cholera include the provision of safe drinking water and improved sanitation and hygiene, ideally in conjunction with oral vaccination. However, difficulties associated with the costs and logistics of these strategies have hampered their widespread implementation. Specific challenges pertaining to oral cholera vaccines (OCVs) include a lack of safe and effective adjuvants to further enhance gut immune responses, the complex and costly multicomponent vaccine manufacturing, limitations of conventional liquid formulation and the lack of an integrated delivery platform. Herein we describe the use of the orally active adjuvant α-Galactosylceramide (α-GalCer) to strongly enhance intestinal bacterium- and toxin-specific IgA responses to the OCV, Dukoral ® in C57BL/6 and BALB/c mice. We further demonstrate the mucosal immunogenicity of a novel multi-antigen, single-component whole-cell killed V. cholerae strain and the enhancement of its immunogenicity by adding α-GalCer. Finally, we report that combining these components and recombinant cholera toxin B subunit in the SmPill ® minisphere delivery system induced strong intestinal and systemic antigen-specific antibody responses. © 2019, The Author(s).

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?